Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | Positive Phase II data of novel anti-CD40L antibody frexalimab in MS

Erik Wallstroem, MD, PhD, Global Head of Development, Neurology and Opthalmology, Sanofi, and Tom Snow, VP, Global Franchise Head, Neurology and Rare Blood Disorders, Sanofi, discuss the emerging data on frexalimab for the treatment of multiple sclerosis (MS). The Phase II study offers promising results, showcasing a pronounced reduction in new active lesions by the 12-week mark. This reduction appeared even more pronounced with a higher dose at the 24-week point. The CD40 ligand inhibitor is unique in that it operates upstream in the immune system, disrupting interactions between T- and B-cells, and also has implications in the innate immune system. Given its novel mechanism and compelling early results, it has sparked significant interest and discussions among experts. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.